logo
Products
Services
Resources
Selection Guides
About
FITC Anti-human CD28 Antibody
9.3
The 9.3 monoclonal antibody binds with human CD28, a 44 kD transmembrane glycoprotein typically located on the surface of natural killer cells and plasma cells. CD28 is a member of vital cellular pathways, namely, the cell surface receptor signaling pathway, apoptotic signaling pathway and T cell receptor signaling pathway. Also, in some organisms, it is involved in the positive regulation of interleukin-4 production, is involved in the positive regulation of inflammatory response to antigenic stimulus and promotes isotype switching to IgG isotypes. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands such as PI3-kinase, CD86 and CD80. CD28 is a very popular antibody target, with over 30000 publications in the last decade. CD28 is vital to costimulatory molecules research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to FITC (ex/em = 491/516 nm). It is compatible with the 488 nm laser and 525/50 nm bandpass filter (for example, as in the Miltenyi Biotec MACSQuant Analyzer 16).
product image
CatalogSize
Price
Quantity
102811I0100 tests
Price
102811I1500 tests
Price
 
Antibody properties

Other namesTp44, T44
Clone9.3
HostMouse
IsotypeIgG2a
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Absorbance (nm)488
Correction factor (280 nm)0.35
Extinction coefficient (cm -1 M -1)
73000
Excitation (nm)491
Emission (nm)516
Quantum yield
0.92
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 21, 2026